Germany · Delayed Price · Currency is EUR Bayer Aktiengesellschaft Earnings Call Transcripts
Fiscal Year 2026
-
The meeting highlighted strong operational progress, debt reduction, and a continued focus on litigation containment and innovation. Shareholders approved all management proposals, including a minimum dividend, while voicing concerns on governance, product safety, and environmental impact.
-
A major class settlement agreement was reached to resolve most U.S. glyphosate litigation, with capped payments over 21 years and increased provisions to EUR 11.8 billion. The deal, pending court approval and influenced by a Supreme Court case, aims to provide closure and strategic flexibility while maintaining strong R&D and financial stability.
-
OCEANIC-STROKE phase III showed asundexian significantly reduced recurrent ischemic and disabling strokes without increasing major or minor bleeding, with consistent benefits across all subgroups and stroke etiologies. The drug's safety and efficacy profile positions it as a potential new standard for secondary stroke prevention.
-
Strong growth in new products and a rejuvenated pipeline are driving a turnaround, with mid-single-digit growth expected from 2027. Key launches in oncology, cardiovascular, and women's health, along with increased R&D productivity and operational agility, position the business for sustained margin expansion and innovation.
Fiscal Year 2025
-
Delivered on upgraded 2025 guidance with EUR 45.5B sales and EUR 4.91 core EPS, while managing major litigation provisions and advancing transformation. 2026 outlook anticipates stable sales and EPS, negative free cash flow due to litigation, and continued investment in growth drivers.
-
Delivered on upgraded 2025 guidance with EUR 45.5B sales and EUR 4.91 core EPS, but faces significant litigation costs and expects negative free cash flow in 2026. All divisions met targets, with ongoing transformation and cost savings from the DSO model.
-
Q3 2025 saw modest sales growth and strong performance from new Pharma launches, offset by FX headwinds and increased litigation provisions. Crop Science and Pharma are on track for full-year targets, while Consumer Health faces continued market challenges, especially in the U.S. and China.
-
Q3 saw modest sales growth in adjusted terms, with strong launches in pharma and ongoing efficiency gains. Litigation provisions increased, and challenging market conditions persist in consumer health and crop science. Full-year guidance is confirmed, with a focus on innovation and deleveraging.
-
Q2 2025 saw modest sales growth, strong Pharma performance, and significant litigation provisions. Guidance for 2025 was raised for sales and earnings, with stable margins expected despite FX and market headwinds. Litigation settlements and cost-saving initiatives remain key priorities.
-
Sales remained flat in H1 2025, with Q2 net sales up 1% year-over-year in adjusted terms but down 4% as reported due to FX headwinds. Litigation provisions and settlements impacted results, while Pharma and Crop Science showed resilience. Guidance for 2025 was raised on sales and earnings.
-
Aims to become the top global consumer health company by 2030, focusing on innovation, omnichannel growth, and expanding in high-potential markets like Asia-Pacific. Financial resilience, portfolio optimization, and science-backed brands drive strategy, with no current plans for divestment.
-
The business is targeting above-market growth, mid-20s EBITDA margin, and over EUR 3 billion in free cash flow by 2029, driven by innovation in Seeds and Traits, Crop Protection, and digital platforms. Strategic cost and cash initiatives, portfolio focus, and expansion into biologicals and biofuels underpin long-term resilience and growth.
-
Q1 2025 saw flat sales, strong pharma growth, and improved free cash flow, with regulatory and FX headwinds impacting crop science. Guidance for 2025 is reaffirmed, with ongoing litigation and cost management actions underway.
-
Q1 2025 saw flat sales overall, with Pharmaceuticals and Consumer Health growth offsetting Crop Science declines. Litigation, regulatory, and FX risks persist, but full-year guidance is reaffirmed and debt reduction remains a priority.
-
The meeting addressed ongoing U.S. litigation, high debt, and strategic transformation, with shareholders approving all management proposals, including a minimum dividend and authorized capital for litigation flexibility. Key priorities remain cost savings, pipeline growth, and legal risk containment.
-
Strong product launches and pipeline advances are offsetting Xarelto losses, with Nubeqa, Kerendia, and Eylea 8mg driving growth. Operational changes and a revamped R&D focus position the business for renewed expansion from 2027, with six potential blockbuster assets.
Fiscal Year 2024
-
2024 results met revised guidance with Pharmaceuticals outperforming, while Crop Science faced margin and sales pressure. 2025 is expected to be challenging, with flat sales, lower earnings, and continued focus on cost savings, debt reduction, and operational transformation.
-
Q3 2024 saw modest group sales growth, but EBITDA and EPS declined due to crop science impairment and FX headwinds. Pharmaceuticals and consumer health offset crop science weakness, with strong launches and margin improvements. 2025 outlook is muted, with regulatory and FX risks persisting.
-
Q3 2024 saw modest group sales growth, with Pharmaceuticals and Consumer Health offsetting Crop Science declines. Litigation, regulatory delays, and FX headwinds weighed on results, but cost-saving and efficiency measures are on track, with 5,500 jobs cut and full-year targets reaffirmed.
-
Finerenone significantly reduced cardiovascular death and heart failure events in patients with mildly reduced or preserved ejection fraction in the FINEARTS-HF phase III trial, with consistent benefits across subgroups and a favorable safety profile. Pooled FINE-HEART analysis confirmed efficacy and safety across cardiorenal outcomes, supporting broader use and regulatory expansion.
-
Q2 2024 saw modest sales growth, improved free cash flow, and strong performance from new pharma launches, offsetting headwinds in crop science and Xarelto generics. Full-year guidance is reaffirmed, with continued focus on innovation, cost control, and pipeline advancement.
-
Q2 saw modest sales growth and improved free cash flow, despite margin pressure and lower EBITDA. Pharma launch products and Consumer Health drove growth, while cost savings and organizational changes progressed as planned. Full-year guidance and financial targets were reaffirmed.